Results 11 to 20 of about 26,349 (219)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
doaj   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +2 more sources

Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening

Nature Communications, 2023
Direct modulation of cardiac myosin function has emerged as a therapeutic target for both heart disease and heart failure. However, the development of myosin-based therapeutics has been hampered by the lack of targeted in vitro screening assays.
Priyanka Parijat, Seetharamaiah Attili, Zoe Hoare, Michael Shattock, Victor Kenyon, Thomas Kampourakis   +5 more
doaj   +1 more source

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +1 more source

Development and prevention of ischemic contracture (“stone heart”) in the pig heart

Frontiers in Cardiovascular Medicine, 2023
Stone heart (ischemic contracture) is a rare and serious condition observed in the heart after periods of warm ischemia. The underlying mechanisms are largely unknown and treatment options are lacking.
Mei Li, Mei Li, Zhi Qin, Erik Steen, Ann Terry, Bowen Wang, Björn Wohlfart, Stig Steen, Anders Arner   +8 more
doaj   +1 more source

Cycling Cross-Bridges Contribute to Thin Filament Activation in Human Slow-Twitch Fibers

Frontiers in Physiology, 2020
It has been shown that not only calcium but also strong binding myosin heads contribute to thin filament activation in isometrically contracting animal fast-twitch and cardiac muscle preparations. This behavior has not been studied in human muscle fibers
Alfredo Jesus López-Dávila, Joseph M. Chalovich, Stefan Zittrich, Birgit Piep, Faramarz Matinmehr, Andras Málnási-Csizmadia, Anna Á. Rauscher, Theresia Kraft, Bernhard Brenner, Robert Stehle   +9 more
doaj   +1 more source

Angiotensin II Facilitates Matrix Metalloproteinase-9-Mediated Myosin Light Chain Kinase Degradation in Pressure Overload-Induced Cardiac Hypertrophy

Cellular Physiology and Biochemistry, 2017
Background/Aims: Angiotensin II (Ang II) has been shown to promote cardiac remodeling during the process of hypertrophy. Myosin light chain kinase (MLCK), a specific kinase for the phosphorylation of myosin light chain 2 (MLC2), plays an important role ...
Shun Wang, Mian Cheng, Zhengqing Hu, Shan Hu, Qiang Zou, Xin Lai, Beilei Liu, Hong Jiang, Congxin Huang, Gang Wu   +9 more
doaj   +1 more source

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

Cardiologia Hungarica, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively ...
Pálinkás, Eszter Dalma, Sepp, Róbert, Olivotto, Iacopo   +2 more
openaire   +2 more sources

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

Journal of Biological Engineering, 2021
Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and ...
Byung-Hyun Cha, Minjin Jung, Angela S. Kim, Victoria C. Lepak, Brett A. Colson, David A. Bull, Youngwook Won   +6 more
doaj   +1 more source

Ginkgolide B Protects Cardiomyocytes from Angiotensin II-Induced Hypertrophy via Regulation of Autophagy through SIRT1-FoxO1

Cardiovascular Therapeutics, 2021
Ginkgolide B (GB) is an active ingredient extracted from Ginkgo biloba leaves. However, the effects of GB on cardiac hypertrophy remain unclear. The study is aimed at determining whether GB could alleviate cardiac hypertrophy and exploring its underlying
Qingyuan Jiang, Ming Lu, Jinyu Li, Zhongsheng Zhu   +3 more
doaj   +1 more source